Literature DB >> 15802893

The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.

Andreas Kreft1, Guntram Büche, Maryam Ghalibafian, Thomas Buhr, Thomas Fischer, Charles James Kirkpatrick.   

Abstract

The incidence of myelofibrosis (MF) among the three major Philadelphia chromosome-negative chronic myeloproliferative disorders, i.e. essential thrombocythaemia (ET), polycythaemia vera (PV) and chronic idiopathic myelofibrosis (CIMF), is not well documented since the diagnostic criteria have recently been redefined by the WHO. Therefore we performed a retrospective analysis of follow-up biopsies of 275 patients with ET, PV and CIMF according to the WHO classification of chronic myeloproliferative disorders. In the diagnostic bone marrow biopsies, MF was observed in 57 of the 136 CIMF patients (42%), 4 of the 73 PV patients (5%) and none of the 66 patients with ET. Within a median observation time of 2.9 years, 34 of the 79 patients with CIMF (43%), 13 of the 69 patients with PV (19%) and 1 of the 66 patients with ET (1.5%)--each initially without MF--developed MF regardless of myelosuppressive therapy. Copyright 2005 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2005        PMID: 15802893     DOI: 10.1159/000083452

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  12 in total

Review 1.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 3.  Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

4.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

5.  [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].

Authors:  K Aumann; A-V Frey; A M May; D Hauschke; C Kreutz; J P Marx; J Timmer; M Werner; H L Pahl
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

6.  Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.

Authors:  Samer A Srour; Susan S Devesa; Lindsay M Morton; David P Check; Rochelle E Curtis; Martha S Linet; Graça M Dores
Journal:  Br J Haematol       Date:  2016-04-07       Impact factor: 6.998

Review 7.  Jak-2 positive myeloproliferative neoplasms.

Authors:  Pablo J Muxí; Ana Carolina Oliver
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 8.  Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.

Authors:  Amy Zhou; Amber Afzal; Stephen T Oh
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 9.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

10.  The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms.

Authors:  M Cem Arı; Deram Büyüktaş; A Emre Eşkazan; Seniz Ongören Aydın; Eda Tanrıkulu; Zafer Başlar; A Nur Buyru; Burhan Ferhanoğlu; Yıldız Aydın; Nükhet Tüzüner; Teoman Soysal
Journal:  Turk J Haematol       Date:  2012-10-05       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.